Takeda Pharmaceutical Company (TAK) Revenue & Revenue Breakdown

Takeda Pharmaceutical Company's yearly revenue for 2024 was $4.26T, representing an increase of 5.87% compared to 2023. The company's yearly revenue for 2023 was $4.03T, representing an increase of 12.85% compared to 2022. TAK's yearly revenue for 2022 was $3.57T, representing an increase of 11.61% compared to 2021.

Takeda Pharmaceutical Company's quarterly revenue for Q4 2024 was $1.05T, a -5.43% decrease from the previous quarter (Q3 2024), and a 9.91% increase year-over-year (Q4 2023). The company's quarterly revenue for Q3 2024 was $1.11T, a 6.53% increase from the previous quarter (Q2 2024), and a 1.33% increase year-over-year (Q3 2023). TAK's quarterly revenue for Q2 2024 was $1.04T, a -1.47% decrease from the previous quarter (Q1 2024), and a 4.07% increase year-over-year (Q2 2023).

Takeda Pharmaceutical Company's revenue growth rate for the last 3 years (2022-2024) was 19.47%, and for the last 5 years (2020-2024) was 29.55%.

Takeda Pharmaceutical Company's revenue streams in r 24 are Adcetris, Adderall XR, Advate, Adynovate/Adynovi, Albumin, Alofisel, Alunbrig, Azilva-F, Dexilant, Elaprase, Entyvio, Feiba, Fosrenol, Gastroenterology, Gattex/Revestive, Iclusig, Immunoglobulin, Intuniv, Leuplin/Enantone, Neuroscience, Ninlaro, Oncology, Other Gastroenterology, Other PDT Immunology, Other Product, Other Product, Other, Other Rare Hematology, PDT Immunology, Pantoloc/Controloc, Rare Diseases, Rare Hematology, Recombinate, Replagal, Takhzyro, Trintellix, Velcade, Vpriv, and Vyvanse/Elvanse. Adcetris generated $109.42B in revenue, accounting 1.28% of the company's total revenue, up 30.37% year-over-year. Adderall XR generated $41.76B in revenue, accounting 0.49% of the company's total revenue, up 71.80% year-over-year. Advate generated $122.91B in revenue, accounting 1.44% of the company's total revenue, up 4.00% year-over-year. Adynovate/Adynovi generated $66.31B in revenue, accounting 0.78% of the company's total revenue, down -0.37% year-over-year. Albumin generated $133.99B in revenue, accounting 1.57% of the company's total revenue, up 10.33% year-over-year. Alofisel generated $3.51B in revenue, accounting 0.04% of the company's total revenue, up 28.92% year-over-year. Alunbrig generated $28.52B in revenue, accounting 0.33% of the company's total revenue, up 38.76% year-over-year. Azilva-F generated $33.64B in revenue, accounting 0.39% of the company's total revenue, down -53.86% year-over-year. Dexilant generated $45.28B in revenue, accounting 0.53% of the company's total revenue, down -34.73% year-over-year. Elaprase generated $91.56B in revenue, accounting 1.07% of the company's total revenue, up 7.31% year-over-year. Entyvio generated $800.92B in revenue, accounting 9.38% of the company's total revenue, up 13.97% year-over-year. Feiba generated $40.54B in revenue, accounting 0.48% of the company's total revenue, down -1.76% year-over-year. Fosrenol generated $13.53B in revenue, accounting 0.16% of the company's total revenue Gastroenterology generated $1.22T in revenue, accounting 14.25% of the company's total revenue, up 11.12% year-over-year. Gattex/Revestive generated $119.25B in revenue, accounting 1.40% of the company's total revenue, up 28.12% year-over-year. Iclusig generated $54.71B in revenue, accounting 0.64% of the company's total revenue, up 15.89% year-over-year. Immunoglobulin generated $644.59B in revenue, accounting 7.55% of the company's total revenue, up 23.43% year-over-year. Intuniv generated $33.56B in revenue, accounting 0.39% of the company's total revenue Leuplin/Enantone generated $107.35B in revenue, accounting 1.26% of the company's total revenue, down -3.56% year-over-year. Neuroscience generated $627.01B in revenue, accounting 7.35% of the company's total revenue, down -1.68% year-over-year. Ninlaro generated $87.36B in revenue, accounting 1.02% of the company's total revenue, down -5.75% year-over-year. Oncology generated $462.36B in revenue, accounting 5.42% of the company's total revenue, up 5.38% year-over-year. Other Gastroenterology generated $82.23B in revenue, accounting 0.96% of the company's total revenue, up 13.59% year-over-year. Other PDT Immunology generated $39.99B in revenue, accounting 0.47% of the company's total revenue, up 14.97% year-over-year. Other Product generated $368.91B in revenue, accounting 4.32% of the company's total revenue, down -18.85% year-over-year. Other Product, Other generated $321.74B in revenue, accounting 3.77% of the company's total revenue, down -11.84% year-over-year. Other Rare Hematology generated $47.3B in revenue, accounting 0.55% of the company's total revenue, up 2.01% year-over-year. PDT Immunology generated $818.57B in revenue, accounting 9.59% of the company's total revenue, up 20.65% year-over-year. Pantoloc/Controloc generated $46.5B in revenue, accounting 0.54% of the company's total revenue, up 2.15% year-over-year. Rare Diseases generated $770.7B in revenue, accounting 9.03% of the company's total revenue, up 6.53% year-over-year. Rare Hematology generated $305.3B in revenue, accounting 3.58% of the company's total revenue, up 0.19% year-over-year. Recombinate generated $12.05B in revenue, accounting 0.14% of the company's total revenue, down -5.58% year-over-year. Replagal generated $73.55B in revenue, accounting 0.86% of the company's total revenue, up 10.21% year-over-year. Takhzyro generated $178.68B in revenue, accounting 2.09% of the company's total revenue, up 17.71% year-over-year. Trintellix generated $104.8B in revenue, accounting 1.23% of the company's total revenue, up 4.71% year-over-year. Velcade generated $5.54B in revenue, accounting 0.06% of the company's total revenue, down -80.05% year-over-year. Vpriv generated $51.3B in revenue, accounting 0.60% of the company's total revenue, up 6.04% year-over-year. Vyvanse/Elvanse generated $423.22B in revenue, accounting 4.96% of the company's total revenue, down -7.85% year-over-year.

For the fiscal year ending Mar 24, the largest source of revenue of Takeda Pharmaceutical Company was Gastroenterology. This segment made a revenue of $1.22T, representing 14.25% of the company's total revenue.